查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949530

神經科學抗體及檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、技術、應用、最終用戶、地區及競爭格局分類），2021-2031年

Neuroscience Antibodies & Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumables, Instruments ), By Technology, By Application, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球神經科學抗體和檢測市場預計將從 2025 年的 46.4 億美元成長到 2031 年的 79.3 億美元，複合年成長率達到 9.34%。

這些抗體和檢測方法是用於檢測、定量和分析神經系統內特定蛋白質和細胞標靶的重要專業生化工具，有助於我們了解神經元功能和病理。推動這一市場發展的主要因素是神經退化性疾病發生率的上升，這增加了對廣泛開展生物標記研究以支持診斷和治療方法開發的需求。因此，對藥物研發的大量投資正在推動對檢驗的檢測工具的需求，阿茲海默症協會的估計也印證了這一趨勢：到2025年，將有720萬65歲及以上的美國人患有老年失智症失智症。

市場概覽
預測期 2027-2031
市場規模：2025年 46.4億美元
市場規模：2031年 79.3億美元
複合年成長率：2026-2031年 9.34%
成長最快的細分市場 消耗品
最大的市場 北美洲

然而，抗體特異性和可重複性方面持續存在的挑戰嚴重阻礙了市場擴張。試劑品質的差異常常導致實驗結果不一致和資源浪費，促使研究人員要求更嚴格的檢驗標準。這些品管方面的挑戰使可靠診斷檢測方法的開發變得複雜，並減緩了新型試劑的商業性化應用，因為科學界仍在努力確保這些工具在其實驗流程中的可靠性。

市場促進因素

全球神經退化性疾病疾病和神經系統疾病的日益普及是推動神經科學抗體和檢測方法需求成長的主要因素。隨著中風、偏頭痛和失智症等疾病負擔的加重，科學界越來越依賴高特異性試劑來繪製神經通路圖譜並驗證病理標靶。這場日益嚴峻的健康危機已將抗體研發的重點轉移到檢驗與中樞神經系統功能障礙相關的、定義不明確的蛋白質聚集體和發炎標記。根據《柳葉刀神經病學》2024年3月刊報道，2021年全球約有34億人患有神經系統疾病，凸顯了提高診斷準確性的至關重要性。

在疫情壓力之外，製藥和生技公司研發投入的激增也積極推動了市場成長。產業領導企業正透過策略性收購拓展其神經科學產品線，而這些收購高度依賴先進的偵測檢驗。例如，BioPharm International在2024年8月報道稱，艾伯維(AbbVie)以87億美元完成了對Cellevelle Therapeutics的收購，以增強其神經科學產品組合，這表明該公司在該領域投入了大量資金。這種投資環境直接推動了試劑消耗，因為檢驗的工具對於臨床成功至關重要。 Technology Networks在2024年1月報告稱，美國FDA在前一年核准了9種新型神經系統藥物，反映了加強研究的實際成果。

市場挑戰

抗體特異性和可重複性持續不足嚴重阻礙了全球神經科學抗體和檢測市場的發展。這個品管難題導致實驗結果出現顯著差異，使研究人員對市售試劑的可靠性產生質疑。當抗體無法與其標靶分子結合或與非標靶蛋白發生交叉反應時，會導致數據不一致和結論錯誤。因此，實驗室在信任新產品之前，必須投入大量資金和時間進行嚴格的內部檢驗。這種營運負擔會延長採購週期，並抑制新檢測方法的應用，因為最終用戶會優先考慮風險規避而非實驗擴展。

這個問題的嚴重性直接阻礙了市場收入的成長。美國國家動物實驗替代、補救和減少中心 (NC3Rs) 在 2024 年的一項評估中發現，在針對 65 種神經科學相關蛋白測試的 614 種市售抗體中，超過 50% 的抗體在至少一個主要應用領域的表徵實驗中失敗。如此高的失敗率需要昂貴的檢驗流程，這限制了研究機構採購和使用這些工具的速度，最終降低了整體市場容量。

市場趨勢

將人工智慧 (AI) 應用於抗體發現和設計，正從根本上改變全球神經科學抗體和檢測市場，滿足提高試劑特異性和加速研發的關鍵需求。傳統的融合瘤檢測耗時且結果易受變異性影響，而 AI 驅動的平台則利用生成演算法In Silico模擬預測最佳結合結構。這項技術變革使得針對神經系統中難成藥標靶的抗體能夠精準設計，從而顯著減輕研究人員的檢驗負擔。根據《Contract Pharma》（2025 年 2 月號）報道，Harbour BioMed 和 Insilico Medicine 已達成策略合作，將各自專有的抗體平台與先進的 AI 技術相結合，以專門解決神經科學領域尚未滿足的需求。這標誌著傳統篩檢方法的突破以及計算設計的廣泛應用。

同時，用於診斷神經退化性疾病的血液生物標記的出現，正在該領域催生一個全新的、高容量的細分市場。傳統上，準確診斷依賴昂貴的PET掃描和侵入性的腦脊髓液採樣，這限制了患者的就診量和重複檢測。如今，市場正轉向基於血漿的免疫檢測，這種分析方法能夠靈敏地檢測磷酸化Tau和BETA-澱粉樣蛋白等病理蛋白，從而使早期檢測工具得以普及。根據《英國醫學雜誌》（BMJ）2025年5月刊報道，美國食品藥物管理局（FDA）核准了首個用於診斷55歲及以上患者阿茲海默症的血液檢測產品Lumipulse。這標誌著監管領域的一個重要里程碑，有助於專業檢測套組的大規模生產，並將神經科學診斷應用於臨床實踐。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球神經科學抗體及檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（耗材（試劑、抗體、檢測試劑盒）、設備（微孔盤讀數儀、免疫檢測分析儀等））
    • 按技術（臨床化學、免疫化學、分子診斷等）
    • 依應用領域（藥物發現與開發、研究、體外診斷）
    • 按最終用戶分類（醫院和診斷中心、製藥和生物技術公司、學術和研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美神經科學抗體及檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲神經科學抗體及檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區神經科學抗體及檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲神經科學抗體和檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲神經科學抗體及檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球神經科學抗體及檢測市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abnova Corp.
  • Bio-Rad Laboratories Inc.
  • Biosensis Pty Ltd.
  • BMG LABTECH GmbH
  • Cell Signaling Technology Inc.
  • Chemie Brunschwig AG
  • Elabscience Bionovation Inc.
  • Enzo Biochem Inc.
  • F. Hoffmann La Roche Ltd.
  • GenScript Biotech Corp.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24004

The Global Neuroscience Antibodies & Assays Market is projected to expand from USD 4.64 Billion in 2025 to USD 7.93 Billion by 2031, achieving a CAGR of 9.34%. These antibodies and assays are specialized biochemical tools essential for detecting, quantifying, and analyzing specific proteins and cellular targets within the nervous system, thereby facilitating the understanding of neural function and pathology. The primary catalyst for this market is the rising incidence of neurodegenerative diseases, which drives the need for extensive biomarker research to support diagnosis and therapeutic development. Consequently, significant investments in pharmaceutical research are boosting the demand for validated detection tools, a trend underscored by the Alzheimer's Association's estimate that 7.2 million Americans aged 65 and older will be living with Alzheimer's dementia in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.64 Billion
Market Size 2031USD 7.93 Billion
CAGR 2026-20319.34%
Fastest Growing SegmentConsumables
Largest MarketNorth America

However, market expansion is significantly hindered by persistent challenges regarding antibody specificity and reproducibility. Inconsistent reagent quality often leads to experimental variability and wasted resources, prompting researchers to demand stricter validation standards. This quality control obstacle complicates the development of reliable diagnostic assays and delays the commercial adoption of novel reagents, as the scientific community faces difficulties in ensuring the reliability of these tools within their experimental workflows.

Market Driver

The increasing global prevalence of neurodegenerative and neurological disorders acts as the primary force driving the demand for neuroscience antibodies and assays. As the burden of conditions such as stroke, migraine, and dementia intensifies, the scientific community increasingly relies on high-specificity reagents to map neural pathways and validate pathological targets. This escalating health crisis has shifted the focus of antibody development toward identifying obscure protein aggregates and inflammatory markers associated with central nervous system dysfunction. According to The Lancet Neurology in March 2024, neurological conditions affected approximately 3.4 billion individuals worldwide in 2021, highlighting the critical necessity for diagnostic precision.

Parallel to this epidemiological pressure, a surge in R&D expenditure by pharmaceutical and biotechnology companies is aggressively fueling market growth. Industry leaders are allocating capital to expand their neuroscience pipelines, frequently through strategic acquisitions that rely heavily on advanced assay validation. For instance, BioPharm International reported in August 2024 that AbbVie finalized an $8.7 billion acquisition of Cerevel Therapeutics to strengthen its neuroscience portfolio, demonstrating the high financial stakes in this sector. This investment environment directly supports reagent consumption, as validated tools are essential for clinical success; Technology Networks noted in January 2024 that the US FDA approved nine novel neurology drugs in the preceding year, reflecting the tangible outcomes of this increased research intensity.

Market Challenge

The persistent lack of antibody specificity and reproducibility significantly impedes the Global Neuroscience Antibodies & Assays Market. This quality control issue creates substantial experimental variability, compelling researchers to question the reliability of commercial reagents. When antibodies fail to bind their intended targets or cross-react with non-target proteins, it leads to irreproducible data and false conclusions. Consequently, laboratories are forced to divert significant capital and time toward rigorous internal validation before they can trust new products, an operational burden that slows the purchasing cycle and discourages the adoption of novel assays as end-users prioritize risk mitigation over experimental expansion.

The magnitude of this issue creates a direct bottleneck for market revenue. According to the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), in 2024, an evaluation revealed that greater than 50% of 614 commercial antibodies tested against 65 neuroscience-related proteins failed characterization experiments in at least one key application. Such high failure rates necessitate expensive verification processes that restrict the speed at which research institutions can procure and utilize these tools, ultimately reducing overall market throughput.

Market Trends

The integration of Artificial Intelligence in antibody discovery and design is fundamentally reshaping the Global Neuroscience Antibodies & Assays Market by addressing the critical need for enhanced reagent specificity and accelerated development. Unlike traditional hybridoma methods which are time-consuming and prone to variability, AI-driven platforms leverage generative algorithms to predict optimal binding structures in silico before wet-lab synthesis. This technological shift allows for the precise engineering of antibodies against difficult-to-drug targets within the nervous system, significantly reducing the validation burden on researchers. According to Contract Pharma, February 2025, Harbour BioMed and Insilico Medicine entered a strategic partnership to combine proprietary antibody platforms with advanced AI capabilities to specifically address unmet medical needs in neuroscience, indicating a departure from standard screening towards the widespread adoption of computational design.

Concurrently, the emergence of blood-based biomarkers for neurodegenerative diagnostics is creating a new, high-volume segment within the sector. Historically, accurate diagnosis relied on expensive PET scans or invasive cerebrospinal fluid collection, restricting patient throughput and repeat testing. The market is now pivoting toward plasma-based immunoassays that can detect pathological proteins such as phosphorylated tau and beta-amyloid with high sensitivity, democratizing access to early detection tools. According to The BMJ, May 2025, the US FDA approved the first blood test, Lumipulse, for diagnosing Alzheimer's disease in patients aged over 55, signifying a major regulatory milestone that drives the mass production of specialized assay kits and moves neuroscience diagnostics into broader clinical practice.

Key Market Players

  • Abnova Corp.
  • Bio-Rad Laboratories Inc.
  • Biosensis Pty Ltd.
  • BMG LABTECH GmbH
  • Cell Signaling Technology Inc.
  • Chemie Brunschwig AG
  • Elabscience Bionovation Inc.
  • Enzo Biochem Inc.
  • F. Hoffmann La Roche Ltd.
  • GenScript Biotech Corp.

Report Scope

In this report, the Global Neuroscience Antibodies & Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuroscience Antibodies & Assays Market, By Product

  • Consumables (Reagents, Antibodies, Assay Kits)
  • Instruments (Microplate Readers, Immunoassay Analyzers, Others)

Neuroscience Antibodies & Assays Market, By Technology

  • Clinical Chemistry
  • Immunochemistry
  • Molecular Diagnostics
  • others

Neuroscience Antibodies & Assays Market, By Application

  • Drug Discovery & Development
  • Research
  • In Vitro Diagnostics

Neuroscience Antibodies & Assays Market, By End user

  • Hospitals & Diagnostics Centers
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • others

Neuroscience Antibodies & Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuroscience Antibodies & Assays Market.

Available Customizations:

Global Neuroscience Antibodies & Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuroscience Antibodies & Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables (Reagents, Antibodies, Assay Kits), Instruments (Microplate Readers, Immunoassay Analyzers, others))
    • 5.2.2. By Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, others)
    • 5.2.3. By Application (Drug Discovery & Development, Research, In Vitro Diagnostics)
    • 5.2.4. By End user (Hospitals & Diagnostics Centers, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Neuroscience Antibodies & Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End user
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neuroscience Antibodies & Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End user
    • 6.3.2. Canada Neuroscience Antibodies & Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End user
    • 6.3.3. Mexico Neuroscience Antibodies & Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End user

7. Europe Neuroscience Antibodies & Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End user
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neuroscience Antibodies & Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End user
    • 7.3.2. France Neuroscience Antibodies & Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End user
    • 7.3.3. United Kingdom Neuroscience Antibodies & Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End user
    • 7.3.4. Italy Neuroscience Antibodies & Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End user
    • 7.3.5. Spain Neuroscience Antibodies & Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End user

8. Asia Pacific Neuroscience Antibodies & Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End user
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neuroscience Antibodies & Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End user
    • 8.3.2. India Neuroscience Antibodies & Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End user
    • 8.3.3. Japan Neuroscience Antibodies & Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End user
    • 8.3.4. South Korea Neuroscience Antibodies & Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End user
    • 8.3.5. Australia Neuroscience Antibodies & Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End user

9. Middle East & Africa Neuroscience Antibodies & Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End user
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neuroscience Antibodies & Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End user
    • 9.3.2. UAE Neuroscience Antibodies & Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End user
    • 9.3.3. South Africa Neuroscience Antibodies & Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End user

10. South America Neuroscience Antibodies & Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End user
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neuroscience Antibodies & Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End user
    • 10.3.2. Colombia Neuroscience Antibodies & Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End user
    • 10.3.3. Argentina Neuroscience Antibodies & Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neuroscience Antibodies & Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abnova Corp.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc.
  • 15.3. Biosensis Pty Ltd.
  • 15.4. BMG LABTECH GmbH
  • 15.5. Cell Signaling Technology Inc.
  • 15.6. Chemie Brunschwig AG
  • 15.7. Elabscience Bionovation Inc.
  • 15.8. Enzo Biochem Inc.
  • 15.9. F. Hoffmann La Roche Ltd.
  • 15.10. GenScript Biotech Corp.

16. Strategic Recommendations

17. About Us & Disclaimer